[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:von-hippel-lindau-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":73,"states":78},"Von Hippel Lindau Syndrome",10,9,[8,16,23,29,36,42,48,54,60,66],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07405164","Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043\u002FLITESPARK-043)",[12],"Phase 3","RECRUITING","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.259860Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",[20],"Phase 2","2026-08-26T02:17:01.714035Z","2026-07-05T05:32:16.796442Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04074135","Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors",[20],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.067216Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04989959","[18F]PT2385 PET\u002FCT in Patients With Renal Cell Carcinoma",[33],"Phase 1","2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.980947Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05955014","Data Collection Protocol for Patients With Von Hippel Lindau Disease",[],"2026-08-26T02:17:36.611194Z","2026-05-13T02:55:06.396063Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT03749980","MyVHL: Patient Natural History Study",[],"2026-08-26T02:18:09.641312Z","2026-05-13T02:55:06.175956Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT00001238","Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",[],"2026-08-26T02:16:34.792807Z","2026-07-05T18:42:10.720145Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT03050268","Familial Investigations of Childhood Cancer Predisposition",[],"2026-08-26T02:17:18.747857Z","2026-05-13T02:55:06.107926Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT01496625","National Eye Institute Biorepository for Retinal Diseases",[],"2026-08-26T02:16:03.788292Z","2026-05-13T02:55:06.073482Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT00102544","Use of Tracking Devices to Locate Abnormalities During Invasive Procedures",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:48.735701Z","2026-06-16T05:54:07.943866Z",[74],{"biomarker":75,"count":76,"slug":77},"Von Hippel-Lindau Disease Tumor Suppressor",4,"von-hippel-lindau-disease-tumor-suppressor",[79,83,86,90],{"state":80,"count":81,"slug":82},"Maryland",5,"maryland",{"state":84,"count":76,"slug":85},"Texas","texas",{"state":87,"count":88,"slug":89},"Massachusetts",3,"massachusetts",{"state":91,"count":88,"slug":92},"Tennessee","tennessee"]